WebIndependent Director @ Inatherys Sas; President and Chief Executive Officer @ Enyo Pharma Sas; Member Board of Directors @ Therachon AG; Global Head of Translational Research … WebINA-03 is under clinical development by Inatherys and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INA-03’s drug-specific ...
Inatherys SAS:Patent,Patent Application,Portfolio Analysis
WebMay 21, 2024 · This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy, pharmacokinetic, and pharmacodynamic evaluation study of INA03 … WebInatherys . Connect to CRM . Save . Summary People Technology Signals & News Similar Companies. Highlights. Active Tech Count 20. About. Inatherys is actively using 20 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF. how do they name cyclones in australia
INA 01 - AdisInsight - Springer
WebINATHERYS is a research company based out of PEPINIERE GENOPOLE ENTREPRISE CAMPUS 1 4 RUE PIERRE FONTAINE, EVRY CEDEX, France. INATHERYS industries Research Biotechnology research INATHERYS' financial review Employees 5 See all INATHERYS' financial information Technologies Apache Load Balancers Google Maps Other Mobile … WebInatherys is a biotechnology company developping monoclonal antibodies for the treatment of cancers and inflammatory diseases. Fontaine, Bourgogne, France 1-10 Private … WebBefore working in industry, Jean- Jacques practised medicine at the Claude Bernard Hospital in Paris, France after gaining his medical degree at the University of Paris. He is a Non- Executive Director at MedDay SAS, Inatherys SAS and Polyphor Limited and Chairman of the Inserm Transfert Initiatives Investment Committee. how much sleep does a 4 year old need